Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies
Copyright © 2024 American Society of Hematology..
Outcomes for relapsed/refractory multiple myeloma (RRMM) patients have dramatically improved following the development and now growing utilization of B cell maturation antigen targeted chimeric antigen receptor (CAR) T cell therapy and bispecific antibody (BsAb) therapy. However, healthcare utilization as a quality-of-life metric in these growing populations has not been thoroughly evaluated. We performed a retrospective cohort study evaluating the frequency and cause of unscheduled healthcare interactions (UHIs) among RRMM patients responding to B-cell maturation antigen targeted BsAbs and CAR T cell therapies (N = 46). This included analysis of remote UHIs including calls to physicians' offices and messages sent through an online patient portal. Our results showed that nearly all (89%) RRMM patients receiving these therapies required a UHI during the first 125 days of treatment, with a mean of 3.7 UHIs per patient. RRMM patients responding to BsAbs were significantly more likely to remotely contact their physicians' offices (1.8-fold increase, p = 0.038) or visit an urgent care center (>3-fold increase, p = 0.012) than RRMM patients responding to CAR T cell therapies. This was largely due to increased reports of mild upper respiratory tract infections in BsAb patients. Our results underscore the need to develop preemptive management strategies for commonly reported symptoms that RRMM patients experience while receiving CAR T cell or BsAb therapies. This preemptive management may significantly reduce unnecessary healthcare utilization in this vulnerable patient population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Blood advances - (2024) vom: 12. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Howard, Anna J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 15.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1182/bloodadvances.2024012871 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371103606 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371103606 | ||
| 003 | DE-627 | ||
| 005 | 20240416233427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240416s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2024012871 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM371103606 | ||
| 035 | |a (NLM)38621239 | ||
| 035 | |a (PII)bloodadvances.2024012871 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Howard, Anna J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 American Society of Hematology. | ||
| 520 | |a Outcomes for relapsed/refractory multiple myeloma (RRMM) patients have dramatically improved following the development and now growing utilization of B cell maturation antigen targeted chimeric antigen receptor (CAR) T cell therapy and bispecific antibody (BsAb) therapy. However, healthcare utilization as a quality-of-life metric in these growing populations has not been thoroughly evaluated. We performed a retrospective cohort study evaluating the frequency and cause of unscheduled healthcare interactions (UHIs) among RRMM patients responding to B-cell maturation antigen targeted BsAbs and CAR T cell therapies (N = 46). This included analysis of remote UHIs including calls to physicians' offices and messages sent through an online patient portal. Our results showed that nearly all (89%) RRMM patients receiving these therapies required a UHI during the first 125 days of treatment, with a mean of 3.7 UHIs per patient. RRMM patients responding to BsAbs were significantly more likely to remotely contact their physicians' offices (1.8-fold increase, p = 0.038) or visit an urgent care center (>3-fold increase, p = 0.012) than RRMM patients responding to CAR T cell therapies. This was largely due to increased reports of mild upper respiratory tract infections in BsAb patients. Our results underscore the need to develop preemptive management strategies for commonly reported symptoms that RRMM patients experience while receiving CAR T cell or BsAb therapies. This preemptive management may significantly reduce unnecessary healthcare utilization in this vulnerable patient population | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Concepcion, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Alice X |e verfasserin |4 aut | |
| 700 | 1 | |a Hamadeh, Issam S |e verfasserin |4 aut | |
| 700 | 1 | |a Hultcrantz, Malin L |e verfasserin |4 aut | |
| 700 | 1 | |a Mailankody, Sham |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Carlyn Rose |e verfasserin |4 aut | |
| 700 | 1 | |a Korde, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Lesokhin, Alexander M |e verfasserin |4 aut | |
| 700 | 1 | |a Hassoun, Hani |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Urvi A |e verfasserin |4 aut | |
| 700 | 1 | |a Maclachlan, Kylee H |e verfasserin |4 aut | |
| 700 | 1 | |a Rajeeve, Sridevi |e verfasserin |4 aut | |
| 700 | 1 | |a Landau, Heather J |e verfasserin |4 aut | |
| 700 | 1 | |a Scordo, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Gunjan L |e verfasserin |4 aut | |
| 700 | 1 | |a Lahoud, Oscar B |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Giralt, Sergio A |e verfasserin |4 aut | |
| 700 | 1 | |a Usmani, Saad Z |e verfasserin |4 aut | |
| 700 | 1 | |a Firestone, Ross S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g (2024) vom: 12. Apr. |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2024012871 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 04 | ||